- One prospective and eight retrospective studies with 4,442 patients were included.
- Significantly lower rates of failure and mortality were seen with cefazolin.
- Subgroup analyses in lower acuity patients were similar to the combined findings.
- Failure and mortality with cefazolin was not significantly lower in higher acuity.
- The overall risk of adverse drug reactions was reduced with cefazolin.